UBS Group
PYXS icon

UBS Group’s Pyxis Oncology PYXS Stock Holding History

UBS Group’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$371K Sell
254,124
-138,642
-35% -$209K ﹤0.01% 6282
2025
Q4 		$452K Buy
392,766
+19,039
+5% +$67.2K ﹤0.01% 6156
2025
Q3 		$830K Sell
373,727
-22,369
-6% -$32.2K ﹤0.01% 5718
2025
Q2 		$436K Sell
396,096
-748
-0.2% -$843 ﹤0.01% 6123
2025
Q1 		$389K Sell
396,844
-49,855
-11% -$66.5K ﹤0.01% 6051
2024
Q4 		$697K Buy
446,699
+418,597
+1,490% +$1.21M ﹤0.01% 5613
2024
Q3 		$103K Buy
28,102
+10,424
+59% +$36.5K ﹤0.01% 6334
2024
Q2 		$58.5K Sell
17,678
-10,572
-37% -$44.4K ﹤0.01% 6570
2024
Q1 		$120K Buy
28,250
+25,295
+856% +$106K ﹤0.01% 6135
2023
Q4 		$5.32K Hold
2,955
– – ﹤0.01% 7795
2023
Q3 		$5.88K Sell
2,955
-4,695
-61% -$10.9K ﹤0.01% 7335
2023
Q2 		$19.6K Buy
7,650
+4,695
+159% +$14.9K ﹤0.01% 6879
2023
Q1 		$11.8K Buy
+2,955
New +$5.9K ﹤0.01% 7472
2022
Q4 		– Sell
-155
Closed – – 11054
2022
Q3 		$0 Sell
155
-212
-58% -$554 ﹤0.01% 10806
2022
Q2 		$1K Sell
367
-1,065
-74% -$2.83K ﹤0.01% 9939
2022
Q1 		$6K Sell
1,432
-3,386
-70% -$24.8K ﹤0.01% 8984
2021
Q4 		$53K Buy
+4,818
New +$55.2K ﹤0.01% 6843

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's PYXS Position: Q1 2026 in Review

UBS Group reduced its Pyxis Oncology (PYXS) stake by 35% in Q1 2026, selling an estimated $209K and leaving 254,124 shares worth $371K. The position accounts for ﹤0.01% of the portfolio, ranked #6282.

UBS Group first reported a position in PYXS in Q4 2021 and has held it in 17 quarters since. The position peaked at $830K in Q3 2025. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • UBS Group held 254,124 shares of Pyxis Oncology worth $371K as of Q1 2026.
  • UBS Group sold 138,642 Pyxis Oncology shares in Q1 2026, an estimated $209K.
  • Pyxis Oncology made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6282 holding.
  • UBS Group first reported a position in Pyxis Oncology in Q4 2021 and has held it in 17 quarters since.
  • UBS Group's Pyxis Oncology position peaked at $830K in Q3 2025.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.